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The Environmental Genome Project is an
effort bythe NIEHS to characterize thevaria-
tions in a number ofimportant human genes
and to relate these differences to susceptibility
ofhumans to chemical and physical agents in
the environment. The long-term goal ofthis
work is to improve human health, primarily
through improved prevention, but also
through treatment when appropriate.
Why is there strong interest in this pro-
ject? At least four major reasons can be iden-
tified. 1) The Human Genome Project is not
finished, but there is broad support in the
biomedical science community for the pro-
gram and a general consensus that the work
will be completed on schedule, even in the
absence ofmajor new developments in tech-
nology. Also, related government efforts are
under way, such as the Centers for Disease
Control National Health and Nutrition
Examination Survey (NHANES) program
and a National Cancer Institute effort to
identify genes that show altered expression
levels in tumors. All ofthis information will
provide a knowledge base to use in disease
prevention and treatment. 2) There is a long
history of interest in inherited diseases,
which resulted in the establishment ofmed-
ical genetics and genetic epideminology as
disciplines (1). Many of these debilitating
diseases were found to be disorders ofprima-
ry metabolism. The reasoning is that if
genetics contributes to rare diseases, then it
should also contribute to more common
ones. 3) Manystudies with experimental ani-
mals show genetic influences on susceptibili-
ty to chemical and physical agents. For
instance, mice deficient in theAhlocus show
differences in cancer incidence and acute
toxicity from a variety of chemicals (2).
Another relevant example in humans is the
differential susceptibility to ultraviolet (UV)
light due to functional differences in DNA
repair genes (3,4). 4) Studies on human drug
metabolism over the past 20 years have pro-
vided convincing evidence ofthe wide vari-
abilityin function ofthe enzymes ofxenobi-
otic metabolism [e.g., cytochromes P450,
N-acetyltransferases, and glutathione (GSH)
transferases] and the in vivo significance of
these variations in the disposition of these
drugs in humans (5-7). In some cases, fatal-
ities can be attributed to these differences
(8). Further, many of these same enzymes
are known to be involved in the bioactiva-
tion and detoxication ofpotentially health-
damaging chemicals found in the environ-
ment (i.e., other than drugs).
Background
The goal of the Environmental Genome
Project is to characterize allelic variants
qualitatively and quantitatively. Variations
from a predominant allele are often
referred to as genetic polymorphisms, a
term used to describe variants occurring at
an incidence of >1%. Polymorphisms are
common among humans. Some have no
functional significance, and identification
ofwhich do and do not have functional
significance will be necessary in order to
interpret the information obtained in the
Environmental Genome Project.
The significance of a polymorphism
depends on the phenotype. Phenotype
changes are observed if 1) the altered
codon produces an amino acid substitution
that changes the catalytic or stability prop-
erties ofthe coded protein; 2) a stop codon
is formed to cause premature termination
of protein synthesis; 3) the rate of tran-
scription to form RNA is decreased or
increased; 4) RNA maturation is prevented
(splice site variants); or 5) mRNA stability
is modified. Only case 1 produces a pro-
tein with different properties, but any of
these cases can raise or lower the amount
ofa particular protein produced.
Two other points should be made. First,
there are emerging technologies that can be
used to rapidly assay mRNA levels. At the
recent NIEHS Symposium on the Environ-
mental Genome (9), P.O. Brown presented
information on the use of chip technology
for this purpose (10). Nongenetic effects on
levels ofmRNA and protein expression can-
not be distinguished from genetic effects in
the absence of further information.
However, ifa genetic polymorphism is iden-
tified, it may be possible to use mRNA
expression to establish the functionality ofa
polymorphism.
Use of Epidemiology:
Strengths and Weaknesses
Considerable effort has been expended on
the use of epidemiology in the analysis of
the effects of physical and chemical agents
in the environment on human health.
Recently, the limitations of epidemiology
have been discussed (11,12). Inherent prob-
lems in most epidemiological analysis
include racial patterns, small sample sizes,
and confounding variables. For these rea-
sons, it is unlikely that epidemiology alone
will be sufficient to establish the signifi-
cance of polymorphisms. An analogy,
although not perfect, is in drug develop-
ment, where clinical trials would not be
done in the absence of at least some basic
mechanistic information about the action
ofa newdrug.
The environmental health epidemiology
literature contains many controversies. The
effects oflow-level electromagnetic radiation
on cancer and pesticides on breast cancer
remain controversial at best (11,13-16).
The field of molecular epidemiology, in
which biomarkers and intermediate end
points are incorporated, is also complicated.
Many associations of genetic polymor-
phisms of enzymes involved in xenobiotic
metabolism with disease have been consid-
ered (17), and meta-analyses are presented
in a recent article by d'Errico et al. (18).
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Odds ratios vary considerably among differ-
ent studies with some ofthe genes. Further,
in many cases there is no established mech-
anistic basis for associations. Although the
Ile/Val 462 polymorphism ofP450 lAI has
been studied extensively, two studies have
shown little if any catalytic differences
between the gene products (19,20). A
reported association ofan epoxidehydrolase
polymorphism with aflatoxin-related hepa-
tocellular carcinoma (21) has also been
questioned on amechanistic basis (22).
Although these are serious concerns
about the discipline ofdassical epidemiolo-
gy, ultimately mechanism-based molecular
epidemiology will be needed to establish
the importance ofparadigms developed in
the laboratory. Returning to the analogy of
drug development, many candidate com-
pounds appear promising, but do not
deliver efficacy in clinical trials.
Problems in Functional
Analysis
As mentioned above, there are serious
caveats in reliance on only epidemiology as
a means to establishing significance of
genetic variations. One reasonable approach
would be to use experimental studies to
establish mechanisms, which can be used as
aguide to doing more enlightened epidemi-
ology. However, there are serious issues to
consider in designing meaningful mechanis-
tic studies on the functional significance of
polymorphisms.
Many of the environmental exposures
are complex mixtures, e.g., tobacco smoke,
smog, and mixtures of solvents in waste
dumps. The etiology is often not precisely
known. Many of these mixtures are not
readily adaptable to laboratory experiments
(23-25). Another issue is the choice of an
appropriate dose ofasingle compound or a
mixture in a cellular system. What dose is
really relevant to the human disease under
consideration? Will this dose be enough to
observe a difference in the laboratory
experiment? Is the end point under obser-
vation reflective of the disease? For
instance, DNA adducts and mutations are
often used as intermediate end points in
cancer studies but may not always be pre-
dictive in the absence ofother factors such
as cell proliferation. We also need to know
whether a certain assay will be predictive
for the target organ under consideration.
Another potential problem is an unex-
pected gain of an unpredicted function.
This appears to be the case in superoxide
dismutase variations related to familial
amyotropic lateral schlerosis, in which the
variant form appears to enhance H202-
dependent oxidations that maybe responsi-
ble for the neurological defect (26,27).
Similarily, a certain P450 variation might
show decreased catalytic activity toward a
model substrate but increased activition of
one more relevant to toxicity, and the
effect might not bepredicted.
Finally, another complication is the
interactions of gene products, an issue
related to haplotypes. This situation can be
readily appreciated with some of the pro-
teins involved in gene regulation, in which
various heterodimers have varying activities
and can be derived from members of two
different gene families, e.g., PPAR/RXRand
fosljun (28,2,). Such situations can also be
seen with enzymes involved in xenobiotic
metabolism, in which one enzyme makes a
product that is used as a substrate by
another. Such paradigms apply to pathways
ofboth activation and detoxication.
Approaches to the NIEHS
Environmental Genome
Project
Although the outline ofthe Environmental
Genome Project was still being developed
at the time ofthe October 1997 workshop,
the general strategy being developed is as
follows. The first stage is defining the pre-
cise goals, genes under investigation, num-
bers and source(s) ofsamples, and the tech-
nologies to be employed in the sequencing
analysis. The first real experimental stage is
the actual sequence analysis. Currently a
rough estimate is that this will involve 200
genes and 1,000 human samples, and ifwe
assume an average of 10 kb/gene then the
prospect is for approximately 2 billion
bases ofsequence analysis (9.
The next stages are less clear (9). One
aspect involves extending the basis to more
individual samples. This can readily be
accomplished using chip technology, in the
context of all of the identified polymor-
phisms. The other aspect involves functional
analysis. Knowledge ofthepolymorphicvari-
ants will be ofsome immediate use in epi-
demiological settings, although the concerns
about understanding significance of poly-
morphisms through only epidemiological
studies have already been expressed.
Functional analysis must involve mechanistic
studies on the roles of the polymorphisms.
However, exactly how the studies will be
designed has not been considered in detail as
ofyet.
Strategies for Functional
Analysis
In some cases assays can be done directly
with humans. For instance, drugs are oxi-
dized by some ofthe P450 enzymes under
consideration here (5). Function can often
be determined in in vitro assays in tissues
obtained from organ donors or surgical
samples, and comparisons with genotype
can be made. Such work can be extended
to in vivo drug studies with humans (30).
Thus, information about polymorphisms
that will be relevant to drug metabolism
itselfcan be rapidly obtained. The question
is how to relate this to diseases with com-
plex etiologies (e.g., chemical mixtures,
unknowncauses).
Another approach, which will probably
be more general, involves heterologous
expression and examination of function.
There are basically two different end points
to use. One is to use a specific assay (e.g.,
for an enzyme such as glutathione peroxi-
dase); the other is to examine thepathology
of the cells following expression of the
polymorphic variants ofeach gene product.
Questions involve appropriateness ofthese
model systems to humans.
A number of model systems exist for
heterologous expression ofgenes (31). They
include bacteria, insect cells, yeast, mam-
malian cells, human cells, and (transgenic)
mice. Human cell lines are usually oftumor
origin and may either involve transient
expression or be stable cell lines. A number
ofissues need to be consideredwhen choos-
ing a system. They include ease of expres-
sion, yields of expressed product, the
endogenous background (i.e., similar pro-
teins to the expressed gene product), the
availability ofdiscernible parameters as end
points to measure, and relevance ofthe sys-
tem to the human situation. The similarity
to humans must be considered with regard
to transcriptional regulation, protein stabili-
ty, and interactionswith othercomponents.
Approaches to Functional
Analysis-A Universal
Approach
There are two approaches to doing func-
tional mechanistic analysis of polymor-
phisms. One strategy is to choose a com-
mon cellular system and express all of the
genes under investigation. This has the
advantage of a common base for compari-
son and could also make use ofthe cheap-
est host system. A possible proposal is to
use yeast to express all of the genes and
their variants. Yeast are eukaryotes and
have an advantage in that many, but not
all, of the gene products involved in yeast
gene regulation have been found to have
human counterparts.
Following expression of genes, the
enzyme activity could be measured, if an
assay exists. The phenotypic changes could
be observed and quantified, if possible.
These results could then be extended to
(human) epidemiologystudies.
There are a number of deficiencies in
this approach. The main one is that the
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assays offunction will be quite different for
the various genes, and some may not be
appropriate for yeast. For instance, the
enzymes involved in xenobiotic metabo-
lism tend to act in concerted pathways, and
yeast do not normally contain much of
these systems.
Multiple Approaches to
Functional Analysis:
Examples
An approach that will probably be more
realistic is one that involves multiple strate-
gies depending upon the gene under con-
sideration. A fewexamples are considered.
In many respects, the enzymes involved
in the metabolism ofxenobiotic chemicals
are easiest to deal with. After establishing
the polymorphisms and frequency distribu-
tion, it may be expedient to first look for a
correlation of the polymorphism and in
vitro catalytic activity in human tissue sam-
ples. Various gene products can also be
expressed readily in simple heterologous
vector systems, and assays ofcatalytic activi-
ty can be done. These enzyme systems have
the advantage that, in many cases, probe
drug substrates are known that can be used
in humans (5), and studies on in vivo phe-
notyping/genotyping may be possible, as
already have been done for enzymes such as
P450s 2D6 and 2C19 (32). If differences
can be identified, work can be extended to
epidemiological settings. A caveat in all of
this is that the test (and probe) substrates
may not be relevant to human health issues,
so aspects such as the chemical etiology of
disease must also be considered.
Another case involves enzymes related
to oxidative stress. Aswith the case above, it
is possible to look for correlation of the
polymorphism and in vitrocatalytic activity
in human tissue samples, ifrelevant samples
and an appropriate assay are available. The
gene products can be expressed in simple
systems, perhaps even microbial ones, and
the abilities of the expressed gene products
can be compared with regard to their abili-
ties to protect from an induced oxidative
stress. Ifmicroorganisms are used, some of
the experiments might be repeated in mam-
malian cells. In the extension ofthe work to
molecular epidemiology, one approach
might be to look for biomarkers of oxida-
tive stress [e.g., F2 isoprostanes (33)] in
humans havingvarious genotypes.
Enzymes that repair chemical and phys-
ical damage to DNA are certainly ofinter-
est in a venture such as the Environmental
Genome Project. One approach might be
to use blood cells from individuals of
defined genotypes and do assays on the
repair oftransfected plasmids with UV- or
carcinogen-damaged DNA (34). The work
could then be extended to cell systems in
which the individual gene products are
overexpressed and then treated with chemi-
cals or physical agents known to produce
the particular kind ofDNA damage under
consideration. The results could then be
extended to epidemiology.
Some of the systems under considera-
tion are complex, and more creativity may
be required. For instance, how will we deal
with polymerases, tumor suppressors, cell
cycle checkpoint-associated proteins, and
signal transduction pathways? In some
cases, coupling may be done in yeast exper-
imental systems. A general problem with
both yeast and mammalian cells is that
wild-type homologs already exist in the
cells and may make interpretation of
expression studies more difficult.
Conclusions
A few more points should be made. In the
above considerations ofthe possible expres-
sion systems to use, one might askwhy not
use the most complex and relevant.
However, ifwe work with 200 genes and
each has 5-10 polymorphisms (a rough but
not unreasonable estimate), we face the
prospect of 1,000-2,000 expressions and
doing the necessary assays. Therefore, some
thought must be given to simplicity ofsys-
tems and rapid assays.
Another problem already mentioned is
that many of the effects may be small in
themselves, and synergism ofmultiple phe-
notypes may be needed for a particular dis-
ease. For instance, one can consider the epi-
demiology work on colon cancer, where a
mixture ofahigh level ofP450 1A2 and the
rapid phenotype for N-acetyltransferase 2
showed a synergism (along with consump-
tion of well-done cooked beef) (35).
Further, we do not really know all of the
functions ofthe genes we are exploring, due
to various aspects ofcoupling. For instance,
some proteins appear to be involved in both
DNArepairand transcription (36-38).
Finally, we have issues of inducibility
and various nongenetic differences. In
many cases the regulatory elements
involved have not been identified, and
these should be the targets for polymor-
phism studies. Also, we should remember
that unknown dietary factors play an
important role in these issues of human
health, and the genotyping studies may or
may not impact on these.
Despite all the caveats presented about
how to proceed with functional analysis,
there is still considerable optimism that the
Environmental Genome Project will be
successful. Accumulation of genotype data
is clearly the first step. Planning is critical
for the functional analysis stage.
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